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Background
• Identifying factors that impair bone accrual during childhood is a critical step toward 
osteoporosis prevention. 
• One potential risk factor not well characterized in childhood is the role of chemicals in the 
environment.
• Perfluoroalkyl substances (PFASs) are synthetic additives used to make clothing, furniture, and 
cookware stain repellant and are detectable in almost all US adults1.
• PFASs act as PPAR-γ agonists,2 androgen receptor antagonists,3 and directly intercalate into 
bone,4 raising the possibility that they may lead to low bone accrual.
• While two population-based studies in adults have shown associations between PFASs and low 
areal bone mineral density (aBMD),5,6 the extent to which PFASs may affect aBMD in children is 
unknown.
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Examine the associations of plasma PFAS concentrations with aBMD Z-score in mid-childhood 
(mean 7.9 years)
Shravanthi M. Seshasayee, BDS MPH,1* Rachel Cluett, MPH,2 Lisa B. Rokoff, MS,3 Sheryl L. Rifas-Shiman, MPH,3
Diane R. Gold, MD MPH,2, 4 Brent Coull, PhD,5 Catherine M. Gordon, MD, MS,6 Clifford J. Rosen, MD,7 Emily Oken, MD 
MPH,3 Sharon K. Sagiv, PhD MPH,8 Abby F. Fleisch, MD MPH1, 9
Results
Exposure (PFASs):
• Perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), perfluorodecanoate (PFDA), 
perfluorohexane sulfonate (PFHxS), 2-(N-methyl-perfluorooctane sulfonamido) acetate 
(MeFOSAA), perfluorononanoate (PFNA)
• Measured in plasma by CDC staff using on-line solid-phase extraction with isotope dilution 
high performance liquid chromatography mass spectrometry
Outcome (aBMD Z-score):
• Total body (excluding the skull) aBMD measured via dual-energy X-ray absorptiometry (DXA)
• Analyzed DXA data with pediatric software (Hologic, version 12.6) and used U.S. national 
reference data to derive age-, sex-, race-, and height-adjusted aBMD Z-scores.7
Statistical analyses:
• Used linear regression to examine associations of each PFAS with aBMD Z-score separately 
in single-PFAS models, and mutually adjusted with other PFASs in a multi-PFAS model
• Examined association between the PFAS mixture and aBMD Z-score via weighted quantile 
sum (WQS) regression. WQS generates a composite mixture index for each participant, 
assigning each PFAS within the mixture a weight reflecting: 
 Strength of its association with aBMD Z-score
 Collinearity with other PFASs within mixture 
• Log2 transformed plasma PFAS concentrations for linear associations with outcome
• Covariates in final models were maternal age, education, annual household income, census 
tract median household income, and child age, sex, race/ethnicity,  and dairy intake, physical 
activity, and year of blood draw
• No evidence for effect modification by sex, so present results without an interaction term
Figure 1. Single and multi-PFAS models showing adjusted associations of individual 
PFAS plasma concentrations with aBMD Z-score
Strengths and Limitations
Strengths
• Among the first studies to evaluate role of toxicants on bone health in childhood
• PFAS concentrations typical for US population during peak production
• Used WQS regression to assess exposure to PFAS mixture
Limitations
• High SES cohort limits generalizability
• Cross sectional analysis, so unable to assess mediation by BMI or pubertal status 
Conclusions References
Each IQR increment in the WQS index was associated with a -0.16 lower aBMD Z-score 
(95% CI: -0.28, -0.04).
• Higher exposure to PFASs was associated with lower aBMD Z-
scores in children.
• Lower exposures to environmental toxicants such as PFASs 
may improve childhood bone accrual and optimize lifelong 
skeletal health.
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Methods
Quartiles of PFOA a plasma concentration
Overall 
n=576
Q1
n=145
Q2 Q3
n=140
Q4
n=144n=147
Mean ± SD or n (% )
Maternal characteristics
Maternal age at enrollment 
(years)
31.8 ± 5.7 29.8 ± 6.5 31.6 ± 5.9 32.7 ± 5.0 33.1 ± 4.5
College graduate (%) 364 (64) 59 (41) 89 (61) 101 (73) 115 (80)
Individual household income (%)
< $40,000/year 85 (16) 39 (30) 20 (14) 15 (11) 11 (8)
$40,001-$70,000/year 89 (16) 25 (19) 23 (17) 22 (16) 19 (13)
> $70,000/year 369 (68) 65 (51) 96 (69) 98 (73) 110 (79)
Census tract median household
income ($10,000/year) 62.7 ± 23.7 53.5 ± 21.0 60.4 ± 23.2 64.7 ± 21.0 72.4 ± 25.5
Child characteristics
Age (years) 7.9 ± 0.8 8.2 ± 1.0 8.0 ± 0.8 7.8 ± 0.7 7.7 ± 0.6
Female (%) 280 (49) 73 (50) 73 (50 101 (45) 71 (49)
Race/ethnicity (%)
White 328 (57) 37 (26) 80 (54) 94 (68) 117 (81)
Black 129 (23) 66 (46) 32 (22) 21 (15) 10 (7)
Other 117 (20) 41 (28) 35 (24) 24 (17) 17 (12)
Dairy intake (servings/wk) 2.2 ± 1.5 2.0 ± 1.5 2.2 ± 1.5 2.3 ± 1.6 2.4 ± 1.5
Physical activity (hrs/wk) 1.9 ± 1.4 1.9 ± 1.5 1.7 ± 1.3 1.9 ± 1.2 1.9 ± 1.5
aBMD Z-score -0.86 ± 0.77 -0.73 ± 0.73 -0.81 ± 0.84 -0.95 ± 0.73 -0.93 ± 0.78
a PFOA quartile minimum and maximum values: <0.1 (LOD)-3.0 ng/mL for Q1, 3.1-4.4 ng/mL for Q2, 4.5-6.1 
ng/mL for Q3, and 6.2-14.3 ng/mL for Q4
Table 1. Participant characteristics overall and by PFOA plasma concentration
Plasma PFAS concentrations (ng/mL)
PFOA PFOS PFDA PFHxS MeFOSAA PFNA
Median (IQR) 4.4 (3.2) 6.4 (5.6) 0.3 (0.3) 1.9 (2.3) 0.3 (0.5) 1.5 (1.2)
5th percentile 1.9 2.1 < LOD a 0.6 < LOD a 0.7
95th percentile 9.8 18.7 0.7 14.7 1.9 5.1
Detection frequency (%) 99.5 99.5 88.4 99.5 65.6 99.5
Spearman correlation coefficients
PFOA 1.00
PFOS 0.79 1.00
PFDA 0.69 0.59 1.00
PFHxS 0.60 0.67 0.34 1.00
MeFOSAA 0.50 0.63 0.32 0.37 1.00
PFNA 0.43 0.35 0.57 0.13 0.22 1.00
a Limit of detection (LOD) was 0.1 ng/mL for all PFASs 
Table 2. Plasma PFAS concentration distributions and correlations 
Study population (Project Viva)
Boston-area pregnant women enrolled 1999-2002 into the prospective Project Viva birth cohort
Enrolled: 
2,128 mother-
infant pairs
Mid-childhood 
follow-up: 
1,116 children
aBMD
measured: 
576 children
Plasma PFAS 
measured: 
653 children
Figure 2. Weights assigned to individual PFASs within the WQS composite index
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